Innovation Pharmaceuticals Inc (IPIX)

[biopa]

Pete. I believe management purposely designed the study with an unusually high number of secondary endpoints. They wanted to be as comprehensive as possible. Something had to stick. Making sure they have collected all of this data has been overwhelmingly. It will be worthwhile, but it still not easy sitting in the waiting room at the maternity ward. Good luck to all longs